A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist).

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Slovin, SF; Melloni, C; Mansor-Lefebvre, S; Neijber, A; Roe, M

Published Date

  • May 20, 2018

Published In

Volume / Issue

  • 36 / 15_suppl

Start / End Page

  • TPS5101 - TPS5101

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2018.36.15_suppl.tps5101